ClinicalTrials.gg
Not yet recruitingNCT07635511AB-HLA-2026Updated Jun 9, 2026

Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies

A Phase 3 interventional study of Acalabrutinib maleate and bortezomib in Hematological Malignancies, Platelet Transfusion Refractoriness (PTR) and HLA Antibodies, sponsored by The First Affiliated Hospital of Soochow University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing bortezomib in Hematologic Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Bortezomib · Hematologic Neoplasms.

Planned enrollment
5th of 10
42 · median 41
Started
2026
the only one that year
Phase 3
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
The First Affiliated Hospital of Soochow University

Among the 10 studies testing bortezomib in Hematologic Neoplasms, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 3, and was the 10th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

3 of the 10 studies testing bortezomib in Hematologic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bortezomib in Hematologic Neoplasms, or all of them as a file.
02

Study summary

Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of bleeding, but is also strongly associated with graft failure and reduced survival after transplantation. HLA class I antibody-mediated alloimmunization is recognized as the most important immunological cause of PTR. HLA antibodies are directly secreted by plasma cells, which are derived from B cells. Therefore, targeting B cells to reduce antibody production is a crucial step in eliminating HLA antibodies. Bruton's tyrosine kinase (BTK) is expressed throughout B cell development from the pre-B cell stage to maturity and supports B cell development, maturation, survival, proliferation, and antibody production by acting as a downstream kinase in the B cell receptor signaling pathway. Bortezomib, a proteasome inhibitor, can selectively induce apoptosis in long-lived plasma cells. The investigators' preliminary exploratory use of a BTK inhibitor in the treatment of PTR with HLA antibodies significantly reduced the mean fluorescence intensity (MFI) of HLA antibodies, improved platelet transfusion outcomes, and demonstrated a favorable safety profile. Based on these findings, the investigators are conducting a prospective, multicenter, randomized controlled two-arm study to investigate the efficacy and safety of acalabrutinib and bortezomib in eliminating HLA antibodies in hematological malignancies patients with PTR.

03

Conditions studied

  • Hematological Malignancies
  • Platelet Transfusion Refractoriness (PTR)
  • HLA Antibodies

Keywords

  • hematological malignancies
  • Platelet transfusion refractoriness
  • HLA antibodies
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with hematological and transfusion refractoriness (24-hour CCI \< 4.5×10⁹/L or PPR \< 20%), and with the highest MFI of HLA antibodies > 8000 ;
  • Age 18-65 years, both male and female;
  • performance status 0-3;
  • Expected survival > 6 months;
  • Patients must be able to understand and be willing to participate in this study, and sign an form.

Exclusion criteria

Exclusion Criteria:

  • to acalabrutinib, bortezomib, or ;
  • Major organ bleeding (central nervous system, lung, intestines) or grade ≥3 bleeding;
  • Hypersplenism;
  • Concurrent use of drugs that may cause excessive consumption (amphotericin B, vancomycin, ATG, interferon, etc.);
  • Disseminated intravascular coagulation, microangiopathic hemolytic anemia;
  • Underlying diseases of vital organs: such as malignant arrhythmia, myocardial infarction, chronic cardiac insufficiency, decompensated liver insufficiency, renal insufficiency, severe coagulation abnormalities, etc.; persistent fever (>38.0°C) for more than 3 days; clinically uncontrolled active infection (including bacterial, fungal, or viral infections), but patients under effective drug therapy are not excluded;
  • Concurrent other progressive ;
  • Patients with cardiac insufficiency: (EF) \<30%, class ≥III cardiac insufficiency;
  • Pregnant or lactating women;
  • Expected survival \<60 days;
  • Currently participating in other clinical drug trials.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Arm A

    Acalabrutinib maleate monotherapy or in combination with bortezomib

    Drug: Acalabrutinib maleate · Drug: bortezomib · Other: HLA-matched or crossmatched irradiated platelets · Drug: human immune globulin

  • Active comparator
    Arm B

    Transfusion of HLA-matched or crossmatched irradiated platelets

    Other: HLA-matched or crossmatched irradiated platelets · Drug: human immune globulin

Interventions

  • DrugAcalabrutinib maleate

    100mg twice a day

  • 1.3mg/m2, d1,4,8,11

  • OtherHLA-matched or crossmatched irradiated platelets

    Transfusion HLA-matched or crossmatched irradiated platelets 10U if platelet count lower than 10\*109/L

  • Drughuman immune globulin

    0.4g/kg.d for 5 days

06

What researchers measure

Primary outcomes

  1. The response rate for anti-HLA antibody clearance

    Complete response: HLA antibody MFI decrease ≥30% (applied to HLA antibody loci with baseline MFI \>8000; median value used for assessment) Partial response: HLA antibody MFI decrease ≥10% and \<30% No response: HLA antibody MFI decrease \<10%, or no decrease or even an increase.

    Time frame: 4 weeks after intervention

  2. CCI (corrected count increments)

    CCI = (platelet increment per ul) x (body surface area in m2)/number of platelets transfused (x 10E11)

    Time frame: 4 weeks after intervention

  3. PPR (percentage platelet recovery)

    PPR = Post-transfusion platelet count-pre-transfusion platelet count (/L) × total blood volume × 100%

    Time frame: 4 weeks after intervention

Secondary outcomes

  1. The incidence of bleeding events

    Time frame: The study period (8 weeks after the initiation of intervention)

  2. The overall survival rate

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pan Y, Zuo Y, Cui Q, Liu S, Dai H, Wu D, Jiang M, Tang X. Treatment outcome and efficacy of desensitization strategies for immunized-PTR in hematological malignancies before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2026 Apr;61(4):437-444. doi: 10.1038/s41409-025-02749-1. Epub 2026 Jan 28. PubMed 41606225 ↗
  • Van Osch TLJ, Oosterhoff JJ, Bentlage AEH, Nouta J, Koeleman CAM, Geerdes DM, Mok JY, Heidt S, Mulder A, Van Esch WJE, Kapur R, Porcelijn L, Van der Schoot CE, De Haas M, Wuhrer M, Voorberg J, Vidarsson G. Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets. Haematologica. 2022 Oct 1;107(10):2432-2444. doi: 10.3324/haematol.2021.280493. PubMed 35354253 ↗
  • Couvidou A, Rojas-Jimenez G, Dupuis A, Maitre B. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects. Front Immunol. 2023 Feb 9;14:1125367. doi: 10.3389/fimmu.2023.1125367. eCollection 2023. PubMed 36845153 ↗
  • Boothby AB, Tanner MK, Alswied A, Youngs D, Bribiesca Rodriguez J, Bikkani T, Cha N, Gernsheimer T, Gimferrer I, Hess JR, Sokol-Hessner L, Marivada S, Nash MG, Flegel WA, Vassallo RR, Stroncek DF, Tsang HC, Panch SR. Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients. Blood Adv. 2024 Sep 10;8(17):4689-4699. doi: 10.1182/bloodadvances.2024014143. PubMed 39028936 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jan 2029, 31 months later.

Of 41 phase 3 interventional studies under Hematologic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 81. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 9, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jan 1, 2029
CompletionEst.
May 31, 2029
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07635511
Responsible party
Xuefeng He (Principal Investigator, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Jun 9, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Jun 9, 2026

Study contacts

Yaqiong Tang
Contact
tangyaqiong@suda.edu.cn
+8618896588075
Xuefeng He
Contact
hexuefeng@suda.edu.cn
+8618914031640
Xuefeng He
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion